Study on the Effects of Elranatamab, Daratumumab, and Lenalidomide Compared to a Standard Treatment in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Inclusion Criteria

• Diagnosed with multiple myeloma, a type of blood cancer.
• Have measurable signs of the disease based on specific medical tests.
• For Part 1: Have either relapsed or refractory multiple myeloma and have tried 1-2 previous treatments, or have newly diagnosed multiple myeloma and are not eligible for a transplant due to age (65 or older) or other health issues.
• For Part 2: Have newly diagnosed multiple myeloma and are not eligible for a transplant due to age or other health conditions that make high-dose chemotherapy and stem cell transplant too risky.
• Have a performance status score of 2 or less, indicating the ability to carry out daily activities with some limitations.
• Not pregnant and willing to use effective birth control.
• For those with relapsed/refractory multiple myeloma: Any side effects from previous treatments should be resolved to a mild level or baseline.

Exclusion Criteria

• Have a condition called smoldering multiple myeloma or other similar blood disorders.
• Have active, uncontrolled infections, including COVID-19, hepatitis B or C, or HIV/AIDS.
• Have had another active cancer within the last 3 years, except for certain skin cancers or very early-stage cancers with low risk of returning.
• For those with relapsed/refractory multiple myeloma: Have received certain previous treatments targeting BCMA or CD38 within the last 6 months, or had a stem cell transplant within the last 3 months.
• For those with newly diagnosed multiple myeloma: Have received any systemic treatment for multiple myeloma except for a short course of steroids.
• Have received a live vaccine within 4 weeks before starting the study treatment.
• Are currently participating in another clinical trial or have taken an investigational drug or vaccine within 30 days before starting this study.